Earnings date set: Hims & Hers will release Q1 2026 results on May 11, with consensus revenue near $616M and EPS at $0.13. Novo Nordisk pact: A March settlement allows sales of brand-name GLP-1 drugs, ...

Healthcare stocks have struggled in 2026. With a year-to-date (YTD) loss of about 6%, that corner of the market has been the ...

Novo Nordisk faces missed guidance as FDA limits on compounded GLP-1s shift the market, while HIMS diversifies offerings.

Hims & Hers Health (NYSE:HIMS) just picked up a high-profile endorsement. JPMorgan analyst Cory Carpenter initiated coverage with an Overweight rating and a $35 price target, framing the telehealth ...

JPMorgan initiated Hims & Hers (HIMS) with Overweight and $35 target, citing Novo Nordisk (NVO) partnership as a turning point legitimizing the GLP-1 business. JPMorgan’s endorsement reframes Hims & ...

Hims & Hers (HIMS) shares surged on FDA peptide tailwinds and a Novo Nordisk partnership to distribute branded Wegovy, giving the company leverage in the GLP-1 market beyond compounded alternatives.

Few telehealth stocks have generated as much momentum in a single week as Hims & Hers Health has managed to pull off recently. Shares of the company, publicly traded on the New York Stock Exchange ...

Hims & Hers Health (HIMS 4.91%), the consumer-focused telehealth platform, closed Tuesday at $29.76, down 4.03%. The stock declined during the regular session after Amazon (AMZN 1.04%) launched a ...

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report first quarter 2026 financial results ...

Hims & Hers has sharply declined, losing nearly 40% YTD and two-thirds from last year's peak. Despite the selloff, I see compelling value in HIMS at its current, compressed valuation. Markets have ...